Lupin has always been very shy in discussing their drug discovery pipeline. However, in an exclusive interview with CNBC-TV18, Dr Kamal Sharma, said that the company is excited about the R&D pipeline, which has 10 lead molecules, and could be potential out-licencing targets by next year.
first published: Nov 16, 2011 07:20 pm
A collection of the most-viewed Moneycontrol videos.
Nifty Sideways But Holds 26,000 Ahead Of MPC Rate Decision| IT & Realty Upbeat| Closing Bell Live
Live: RBI Policy Expectations| Rupee Slide, Strong GDP & Soft Inflation – Will MPC Cut Or Pause?
Nifty Holds Key Support; Volatile Trade Likely on Sensex Expiry | Opening Bell Live
Rupee Slide Weighs Heavy As Nifty Tests 25,900| Midcaps See Sharp Cuts| Closing Bell Live
